New drug duo targets Tough-to-Treat stomach and pancreatic cancers
NCT ID NCT07446270
Summary
This study is testing whether combining two drugs, tunlametinib and an anti-EGFR antibody, can help control advanced colorectal or pancreatic cancer in patients whose cancer has a specific genetic change called a RAS mutation. It will involve about 90 adults whose cancer has worsened despite standard treatments. The main goal is to see how well the combination shrinks tumors and controls the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT FOR ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.